1:56 PM
 | 
Feb 07, 2019
 |  BC Extra  |  Financial News

Arch-backed HiberCell launches with over $60M to target dormant cancer cells

HiberCell Inc. (New York, N.Y.) launched Thursday with $60.8 million in series A funding from Arch Venture Partners to develop therapies that prevent cancer relapse and metastasis. HiberCell said it is the first company exclusively focused on detecting and targeting dormant cancer cells.

Cancer recurrence is driven by dormant disseminated tumor cells (DTCs) that lodge in distant...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >